☆ 4.7 Meeting Abstract

Health-related quality-of-life (HRQOL) impact of dabrafenib (D) and trametinib (T) vs BRAF inhibitor (BRAFi) monotherapy by lactate dehydrogenase (LDH) in patients (pts) with BRAF V600-mutant melanoma

ANNALS OF ONCOLOGY (2016)

Journal

ANNALS OF ONCOLOGY

Volume 27, Issue -, Pages -

Publisher

OXFORD UNIV PRESS

DOI: 10.1093/annonc/mdw379.32

Keywords

-

Categories

Oncology

Funding

GlaxoSmithKline

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Dermatology

First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma

Chang Gon Kim, Miso Kim, Jieon Hwang, Seung Tae Kim, Minkyu Jung, Kyoo Hyun Kim, Kyung Hwan Kim, Jee Suk Chang, Woong Sub Koom, Mi Ryung Roh, Kee Yang Chung, Tae Min Kim, Sang Kyum Kim, Jeeyun Lee, Sang Joon Shin

Summary: This study compared the outcomes of first-line pembrolizumab and dabrafenib/trametinib treatment for patients with advanced melanoma with BRAF mutations. The results showed that first-line pembrolizumab treatment resulted in longer overall survival, suggesting it may be a better treatment option.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study

Xue Bai, Ahmed Shaheen, Charlotte Grieco, Paolo D. d'Arienzo, Florentia Mina, Juliane A. Czapla, Aleigha R. Lawless, Eleonora Bongiovanni, Umberto Santaniello, Helena Zappi, Dominika Dulak, Andrew Williamson, Rebecca Lee, Avinash Gupta, Caili Li, Lu Si, Martina Ubaldi, Naoya Yamazaki, Dai Ogata, Rebecca Johnson, Benjamin C. Park, Seungyeon Jung, Gabriele Madonna, Juliane Hochherz, Yoshiyasu Umeda, Yasuhiro Nakamura, Christoffer Gebhardt, Lucia Festino, Mariaelena Capone, Paolo Antonio Ascierto, Douglas B. Johnson, Serigne N. Lo, Georgina L. Long, Alexander M. Menzies, Kenjiro Namikawa, Mario Mandala, Jun Guo, Paul Lorigan, Yana G. Najjar, Andrew Haydon, Pietro Quaglino, Genevieve M. Boland, Ryan J. Sullivan, Andrew J. S. Furness, Ruth Plummer, Keith T. Flaherty

Summary: In patients with stage III BRAF V600-mutant melanoma, adjuvant D/T therapy yielded better relapse-free survival (RFS) than PD-1 therapy, with higher transient toxicity and lower persistent toxicity, while maintaining comparable overall survival (OS). Larger prospective trials with longer follow-up are needed to further evaluate the outcomes of D/T compared to PD-1.

ECLINICALMEDICINE (2023)

Add to Collection

Article Oncology

Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial

Lili Mao, Ya Ding, Xue Bai, Xinan Sheng, Jie Dai, Zhihong Chi, Chuanliang Cui, Yan Kong, Yun Fan, Yanjun Xu, Xuan Wang, Bixia Tang, Bin Lian, Xieqiao Yan, Siming Li, Li Zhou, Xiaoting Wei, Caili Li, Jun Guo, Xiaoshi Zhang, Lu Si

Summary: The combination treatment of dabrafenib and trametinib shows long-term survival benefits in Chinese patients with BRAF V600-mutant, unresectable or metastatic acral/cutaneous melanoma. The study found a high objective response rate and overall survival rate in these patients.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma

Carola Berking, Elisabeth Livingstone, Dirk Debus, Carmen Loquai, Michael Weichenthal, Ulrike Leiter, Felix Kiecker, Peter Mohr, Thomas K. Eigentler, Janina Remy, Katharina Schober, Markus V. Heppt, Imke von Wasielewski, Dirk Schadendorf, Ralf Gutzmer

Summary: The outcome of advanced melanoma patients has greatly improved over the past 15 years. Targeted therapies blocking BRAF or inhibiting immune checkpoints have shown significant efficacy in improving overall survival. The COMBI-r study confirms the efficacy of dabrafenib plus trametinib in routine clinical practice and provides additional data in patients with brain metastases or previous treatments.

CANCERS (2023)

Add to Collection

Article Oncology

Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BOF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib

Philippe Saiag, Caroline Robert, Jean -Jacques Grob, Laurent Mortier, Olivier Dereure, Celeste Lebbe, Sandrine Mansard, Florent Grange, Eve-Marie Neidhardt, Thierry Lesimple, Laurent Machet, Christophe Bedane, Herve Maillard, Sophie Dalac-Rat, Alexandra Szenik, Charlee Nardin, Amine Denden, Caroline Dutriaux

Summary: This large prospective study in France investigated the treatment outcomes of BRAF V600-mutant melanoma patients receiving dabrafenib and trametinib combination therapy. The study confirmed previous findings that factors such as lactate dehydrogenase levels, Eastern Cooperative Oncology Group Performance Status, number of metastatic sites, and presence of brain metastasis are associated with progression-free survival in these patients.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Article Dermatology

Final analysis of a post-marketing surveillance study of dabrafenib and trametinib combination therapy in Japanese patients with unresectable malignant melanoma with BRAF V600 mutation

Tomoaki Kaizuka, Ryohei Kurihara, Miki Harumiya, Takayuki Kimura, Naoko Ushida

Summary: This study investigated the safety and efficacy of combination therapy with dabrafenib and trametinib for Japanese patients with malignant melanoma. The results showed that this treatment approach was safe and effective in a real-world clinical setting in Japan.

JOURNAL OF DERMATOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Complete response of metastatic BRAF V600-mutant anaplastic thyroid cancer following adjuvant dabrafenib and trametinib treatment: A case report

Sang Jae Lee, Si-Youn Song, Min Kyoung Kim, Hyung Gyun Na, Chang Hoon Bae, Yong-Dae Kim, Yoon Seok Choi

Summary: Adjuvant chemotherapy with dabrafenib plus trametinib is highly effective for the treatment and prevention of recurrent anaplastic thyroid cancer with BRAF mutation following surgery.

WORLD JOURNAL OF CLINICAL CASES (2023)

Add to Collection

Article Oncology

Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study

Caroline A. Nebhan, Douglas B. Johnson, Ryan J. Sullivan, Roda N. Amaria, Keith T. Flaherty, Jeffrey A. Sosman, Michael A. Davies

Summary: This study found that trametinib showed significant clinical activity in non-V600 BRAF mutation and BRAF fusion metastatic melanoma, suggesting that all patients with metastatic melanoma should undergo sequencing of the BRAF gene. The study concluded that trametinib had considerable activity in a small population of patients, highlighting the importance of sequencing to identify genomic alterations.

ONCOLOGIST (2021)

Add to Collection

Article Oncology

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF(V600) Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

Paolo A. Ascierto, Brigitte Dreno, James Larkin, Antoni Ribas, Gabriella Liszkay, Michele Maio, Mario Mandala, Lev Demidov, Daniil Stroyakovskiy, Luc Thomas, Luis de la Cruz-Merino, Victoria Atkinson, Caroline Dutriaux, Claus Garbe, Jessie Hsu, Surai Jones, Haocheng Li, Edward McKenna, Athina Voulgari, Grant A. McArthur

Summary: The long-term follow-up of the coBRIM study confirmed the extended clinical benefit and safety profile of cobimetinib plus vemurafenib compared to vemurafenib monotherapy in patients with BRAF(V600) mutation-positive advanced melanoma. The study showed improved progression-free survival and overall survival in the cobimetinib plus vemurafenib group, with the safety profile remaining consistent with previous reports.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma

Ernesto Rossi, Giovanni Schinzari, Francesco Cellini, Mario Balducci, Mariangela Pasqualoni, Brigida Anna Maiorano, Bruno Fionda, Silvia Longo, Francesco Deodato, Alessandro Di Stefani, Ketty Peris, Maria Antonietta Gambacorta, Giampaolo Tortora

Summary: BRAF and MEK inhibitors have changed the clinical management of metastatic melanoma, but their combination with radiotherapy needs careful monitoring for potential toxicity. This study reports the successful use of fractionated radiotherapy in metastatic melanoma patients receiving BRAF and MEK inhibitors, without significant adverse events. These results suggest that interruption of targeted therapy during radiotherapy for oligoprogressive disease can be avoided.

BIOMEDICINES (2023)

Add to Collection

Review Medicine, General & Internal

Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review

Morena Fasano, Carminia Maria Della Corte, Marianna Caterino, Mario Pirozzi, Raffaele Rauso, Teresa Troiani, Giulia Martini, Stefania Napolitano, Floriana Morgillo, Fortunato Ciardiello

Summary: In this case report, a patient with recurrent craniopharyngioma harboring BRAF V600E mutation received targeted therapy with a combination of BRAF inhibitor and MEK inhibitor, showing significant clinical improvement and rapid response.

FRONTIERS IN MEDICINE (2022)

Add to Collection

Article Oncology

Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma

Walid Shalata, Rachel Steckbeck, Ilya Polishchuk, Ahron Yehonatan Cohen, Keren Rouvinov, Margarita Tokar, Ashraf Abu Jama, Omar Abu Saleh, Kim Sheva, Alexander Yakobson

Summary: This case report presents a patient with metastatic melanoma complicated by hyperbilirubinemia. The patient had BRAF V600E-mutated melanoma with metastases in various organs. Due to a lack of guidelines for treating melanoma patients with hyperbilirubinemia, a panel of specialists discussed between treatment initiation and supportive care. The patient eventually received combination therapy with dabrafenib and trametinib, resulting in a significant therapeutic and radiological response.

FRONTIERS IN ONCOLOGY (2023)

Add to Collection

Article Oncology

Efficacy of dabrafenib/trametinib in pancreatic ductal adenocarcinoma with BRAF NVTAP deletion: A case report

Ji Eun Shin, Ho Jung An, Hyung Soon Park, Hyunho Kim, Byoung Yong Shim

Summary: Studies have shown that the BRAF V600E mutation is common in KRAS wild-type PDAC and can be targeted for treatment, resulting in partial response. Further evidence suggests that short in-frame deletions of BRAF also have oncogenic function.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Oncology

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

V Subbiah, R. J. Kreitman, Z. A. Wainberg, J. Y. Cho, J. H. M. Schellens, J. C. Soria, P. Y. Wen, C. C. Zielinski, M. E. Cabanillas, A. Boran, P. Ilankumaran, P. Burgess, T. Romero Salas, B. Keam

Summary: This study evaluated the efficacy and safety of dabrafenib plus trametinib in the treatment of BRAF V600E-mutant ATC. The results showed that the combination therapy provided significant clinical benefits and manageable toxicity, leading to improved long-term survival in patients with ATC.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Oncology

Head-to-Head Comparison of BRAF/MEK Inhibitor Combinations Proposes Superiority of Encorafenib Plus Trametinib in Melanoma

Alexander Schulz, Jennifer Raetz, Paula C. Karitzky, Lisa Dinter, Julia K. Tietze, Isabell Kolbe, Theresa Kaeubler, Bertold Renner, Stefan Beissert, Friedegund Meier, Dana Westphal

Summary: In the past, metastatic melanoma was often considered incurable, but with the introduction of new therapies, such as BRAF and MEK inhibitors, significant progress has been made in the treatment of this disease. This study compared different combinations of BRAF and MEK inhibitors, with encorafenib/trametinib showing the highest anti-tumor activity in both BRAF- and NRAS-mutated melanoma cells. These findings suggest that this particular combination may be more effective than current standard treatments and warrants further investigation in clinical trials to potentially improve overall responses in melanoma patients.

CANCERS (2022)

Add to Collection

Article Ophthalmology

Determinants of Long-Term Survival in Metastatic Choroidal and Ciliary Body Melanoma

Elina S. Rantala, Raffaele Parrozzani, Micaela M. Hernberg, Vanna Chiarion-Sileni, Tero T. Kivela, Edoardo Midena

Summary: The study aims to build and validate a prognostic model for predicting long-term overall survival in metastatic choroidal and ciliary body melanoma. The study analyzed the predictors of intermediate and long-term survival in a Finnish cohort, and validated the models using an Italian cohort. The results showed that alkaline phosphatase or lactate dehydrogenase >2 times the upper normal limit essentially precluded long-term survival, and the most robust predictor was distant metastasis-free interval >42 months.

AMERICAN JOURNAL OF OPHTHALMOLOGY (2023)

Add to Collection

Article Oncology

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

Jeffrey S. Weber, Dirk Schadendorf, Michele Del Vecchio, James Larkin, Victoria Atkinson, Michael Schenker, Jacopo Pigozzo, Helen Gogas, Stephane Dalle, Nicolas Meyer, Paolo A. Ascierto, Shahneen Sandhu, Thomas Eigentler, Ralf Gutzmer, Jessica C. Hassel, Caroline Robert, Matteo S. Carlino, Anna Maria Di Giacomo, Marcus O. Butler, Eva Munoz-Couselo, Michael P. Brown, Piotr Rutkowski, Andrew Haydon, Jean-Jacques Grob, Jacob Schachter, Paola Queirolo, Luis de la Cruz-Merino, Andrew Haydon, Jean-Jacques Grob, Jacob Schachter, Paola Queirolo, Luis De La Cruz-Merino, Andre van der Westhuizen, Alexander M. Menzies, Sandra Re, Tuba Bas, Veerle de Pril, Julia Braverman, Daniel J. Tenney, Hao Tang, Georgina Long

Summary: The CheckMate 915 trial compared adjuvant nivolumab plus ipilimumab with nivolumab alone in patients with resected melanoma. The study found that there was no significant difference in recurrence-free survival between the two treatment groups.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Dermatology

IFN-y Signaling Sensitizes Melanoma Cells to BH3 Mimetics

Zizhen Ming, Su Yin Lim, Ashleigh Stewart, Bernadette Pedersen, Elena Shklovskaya, Alexander M. Menzies, Matteo S. Carlino, Richard F. Kefford, Jenny H. Lee, Richard A. Scolyer, Georgina V. Long, Helen Rizos

Summary: Immunotherapy targeting PD-1 and/or CTLA4 can lead to durable responses in some melanoma patients. However, treatment resistance and lack of response are common. This study identifies a vulnerability in melanoma driven by immune cell activity, providing potential strategies for combination therapies.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2023)

Add to Collection

Article Pathology

Genomic Profiling of Metastatic Basal cell Carcinoma Reveals Candidate Drivers of Disease and Therapeutic Targets

Ismael A. Vergara, Karina Aivazian, Matteo S. Carlino, Alexander D. Guminski, Nigel G. Maher, Kerwin F. Shannon, Sydney Ch'ng, Robyn P. M. Saw, Georgina Long, James S. Wilmott, Richard A. Scolyer

Summary: Basal cell carcinomas (BCCs) are the most common malignant tumors in humans and are usually easily managed by surgery or topical therapies. However, metastatic BCCs are rare and may have distinct biological characteristics. Through genomic profiling, aberrant activation of Hedgehog signaling and alterations in multiple signaling pathways were identified in metastatic BCCs. The presence of clonal origin in matched local recurrences and metastases suggests that molecular profiling can assist in determining the nature and origin of poorly differentiated metastatic tumors. Dysregulation of the Hippo and PI3K/AKT pathways were implicated in the metastatic progression of BCCs, making them potential therapeutic targets.

MODERN PATHOLOGY (2023)

Add to Collection

Article Oncology

Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma

Julia Lai-Kwon, Sarah Jacques, Matteo Carlino, Naima Benannoune, Caroline Robert, Clara Allayous, Barouyr Baroudjian, Celeste Lebbe, Lisa Zimmer, Zeynep Eroglu, Turkan Ozturk Topcu, Florentia Dimitriou, Andrew Haydon, Serigne N. Lo, Alexander M. Menzies, Georgina Long

Summary: This study investigates the efficacy of a combination therapy strategy involving low-dose ipilimumab (IPI) and an anti-PD1 antibody in advanced melanoma. The results show that the majority of patients who progress following low-dose IPI and subsequently receive IPI 3 mg/kg (IPI3) have a positive response to this treatment. This suggests that the dosage of IPI is critical for certain patients.

EUROPEAN JOURNAL OF CANCER (2023)

Add to Collection

Article Immunology

Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy

Jake R. Thompson, Julia Lai-Kwon, Rachael L. Morton, Alexander D. Guminski, Maria Gonzalez, Victoria Atkinson, Shahneen Sandhu, Michael P. Brown, Alexander M. Menzies, Grant A. McArthur, Serigne N. Lo, Georgina Long, Iris Bartula

Summary: This study investigated the health-related quality of life (HRQoL) of melanoma brain metastasis (MBM) patients undergoing ipilimumab-nivolumab or nivolumab treatment for 18 weeks. The results showed that there was no significant deterioration in HRQoL for MBM patients treated with either ipilimumab-nivolumab or nivolumab within the first 18 weeks of treatment initiation.

IMMUNOTHERAPY (2023)

Add to Collection

Article Infectious Diseases

Changes in body mass index, weight, and waist-to-hip ratio over five years in HIV-positive individuals in the HIV Heart Aging Study compared to the general population

Laven Mavarani, Sarah Albayrak-Rena, Anja Potthoff, Martin Hower, Sebastian Dolff, Stefanie Sammet, Felix Maischack, Dirk Schadendorf, Boerge Schmidt, Stefan Esser

Summary: Our study evaluated the changes in weight, body-mass-index (BMI), and waist-to-hip ratio (WHR) over a 5-year follow-up in people living with HIV (PLH) compared to the general population. The results showed that PLH had greater increases in weight and BMI after 5 years, but lower WHR change compared to the general population.

INFECTION (2023)

Add to Collection

Article Clinical Neurology

Case series: Immune checkpoint inhibitor-induced transverse myelitis

Sophie Chatterton, Shuo Xi, Jessica Xi Jia, Martin Krause, Georgina V. Long, Victoria Atkinson, Alexander M. Menzies, Suran L. Fernando, Therese Boyle, Samuel Kwok, Andrew Duggins, Deme Karikios, John D. E. Parratt

Summary: Four cases of ICI-induced transverse myelitis were reported in Australia. All patients had clinical evidence of inflammation in the cerebrospinal fluid and longitudinally extensive transverse myelitis on MRI spine. Prompt intensive immunomodulation is favored to reduce morbidity and mortality, and there is a risk of relapse after cessation of immunomodulatory therapy.

FRONTIERS IN NEUROLOGY (2023)

Add to Collection

Article Oncology

Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial

Dirk Schadendorf, Hussein Tawbi, Evan J. Lipson, F. Stephen Hodi, Piotr Rutkowski, Helen Gogas, Christopher D. Lao, Jean-Jacques Grob, Andriy Moshyk, Jennifer Lord-Bessen, Melissa Hamilton, Shien Guo, Ling Shi, Sarah Keidel, Georgina Long

Summary: The RELATIVITY-047 trial demonstrates that the fixed-dose combination of nivolumab plus relatlimab improves progression-free survival in patients with advanced melanoma while maintaining stable health-related quality of life. Although the combination treatment is associated with a higher incidence of severe adverse events, patients' discomfort with these events is low, supporting NIVO + RELA as a first-line treatment option.

EUROPEAN JOURNAL OF CANCER (2023)

Add to Collection

Article Oncology

Deep learning detection of melanoma metastases in lymph nodes

Philipp Jansen, Daniel Otero Baguer, Nicole Duschner, Jean Le'Clerc Arrastia, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Joerg Schaller, Klaus Georg Griewank

Summary: In this study, a deep learning method was used to analyze histological tissue sections of melanoma patients, enabling accurate detection of lymph node metastasis and providing valuable reference for pathologists. The method was able to identify the size and classify the tumor, which is of great significance for prognosis assessment and treatment planning.

EUROPEAN JOURNAL OF CANCER (2023)

Add to Collection

Article Oncology

COLUMBUS-AD: phase III study of adjuvant encorafenib plus binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma

Alexander C. J. van Akkooi, Axel Hauschild, Georgina Long, Mario Mandala, Michal Kicinski, Anne-Sophie Govaerts, Isabelle Klauck, Monia Ouali, Paul C. Lorigan, Alexander M. M. Eggermont

Summary: Stage IIB/IIC melanoma has a high risk of recurrence, but adjuvant therapies such as anti-PD-1 antibodies and BRAF MEK inhibitor therapy show promise in improving survival. The ongoing COLUMBUS-AD trial investigates the effectiveness of a BRAF-MEK inhibitor combination therapy in patients with BRAF-mutated IIB/IIC melanoma.

FUTURE ONCOLOGY (2023)

Add to Collection

Meeting Abstract Oncology

Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study

Jason J. Luke, Paolo Antonio Ascierto, Muhammad Adnan Khattak, Luis de la Cruz Merino, Michele Del Vecchio, Piotr Rutkowski, Francesco Spagnolo, Jacek Mackiewicz, Vanna Chiarion-Sileni, John M. M. Kirkwood, Caroline Robert, Jean-Jacques Grob, Federica de Galitiis, Dirk Schadendorf, Matteo S. Carlino, Larry Wu, Mizuho Fukunaga-Kalabis, Clemens Krepler, Alexander M. Eggermont, Georgina V. Long

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

Colitis due to immunotherapy with anti-PD-1: a case series

M. De Ruvo, B. Barberio, F. Zingone, L. Bonanno, A. Dal Maso, F. Stefano, V. Chiarion Sileni, E. V. Savarino

JOURNAL OF CROHNS & COLITIS (2023)

Add to Collection

Article Oncology

The features and management of acquired resistance to PD1-based therapy in metastatic melanoma

Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies

Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.

EUROPEAN JOURNAL OF CANCER (2024)

Add to Collection

Article Oncology

Deep learning based histological classification of adnex tumors

Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank

Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.

EUROPEAN JOURNAL OF CANCER (2024)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.